Unicycive Therapeutics: Advancing Breakthroughs in Kidney Disease Therapies
1 year ago
Unicycive Therapeutics
NASDAQ: UNCY
kidney disease
pipeline
indications
Renazorb
hyperphosphatemia
chronic kidney disease
UNI 494
acute kidney injury
commercialize
A biotech dedicated to developing treatments for unmet medical needs, Unicycive Therapeutics (NASDAQ: UNCY) is currently advancing two programs focused on kidney disease and intends to expand its pipeline to target additional indications within and outside kidney disease. Unicycive is preparing to commercialize and launch its lead therapy, Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease and is continuing development of UNI 494 for treatment of acute kidney injury. Visit UNCYinfo.com to learn more.
Loading comments...
-
9:51
RedChip
1 year agoUnicycive Therapeutics: Addressing a $2.5 Billion Global Market Opportunity in Kidney Disease
-
27:38
1AESidneyAndBard
1 year agoThe Chronic Kidney Disease Miracle: How to Improve Your Kidney Function Naturally
14 -
3:02
1AESidneyAndBard
1 year agoDiscover the Secret to Healthy Kidneys: The Kidney Disease Solution
33 -
27:38
redbubblespreadshop
1 year agoThe Chronic Kidney Disease Breakthrough: Say Goodbye to Dialysis
111 -
2:34
Matthew Lennon Healer @ World Healing Centre
10 months agoChronic Kidney Disease
33 -
1:51:52
TheRealTruthAboutHealth
7 months agoPlant-Based Kidney Protection Made Easy-Whole Patient Strategies, CKD To Dialysis
194 -
1:06
Cryptostreets
2 months agoMini Kidneys Uncover Big Advances in Polycystic Kidney Disease Research
27 -
2:11
One4AllChannel
1 year agoI Used To Suffer Chronic Kidney Disease
7 -
5:33
Biological Medicine
9 months agoChronic kidney disease and how to improve your kidney health
5941 -
27:38
100freepresentations
1 year agoBeat Chronic Kidney Disease: The Ultimate Solution